Iterum Therapeutics plc Announces Delisting from Nasdaq and Winding Up Proceedings

Key Points for Investors

• Delisting from Nasdaq: Iterum Therapeutics plc (“the Company”) has received formal notice that its ordinary shares will be delisted from The Nasdaq Stock Market LLC, with trading to be suspended at the opening of business on April 1, 2026.
• Winding Up Process: The Company is undergoing a winding up process conducted by joint provisional liquidators from Teneo Restructuring (Ireland) Limited, namely Damien Murran and Jennifer McMahon.
• No Further SEC Filings: Due to limited cash resources and the winding up process, the Company does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or make any other future filings with the SEC.
• Potential Impact on Shareholders: The process may impact shareholders’ ability to realize any value or recovery during the winding up, and future outcomes remain highly uncertain.

Detailed Article

Iterum Therapeutics plc, a pharmaceutical company previously trading under the symbol ITRM on Nasdaq, has formally notified investors that its shares will be delisted following a failure to maintain the minimum bid price required for continued listing on the Nasdaq Capital Market.

On February 24, 2026, the Company received a delisting determination letter from Nasdaq after its ordinary shares failed to maintain a minimum bid price of \$1.00 per share. Initially, Iterum Therapeutics requested a hearing to appeal the delisting determination; however, the Company subsequently withdrew its appeal. As a result, Nasdaq staff have determined that the shares will be delisted and suspended from trading effective April 1, 2026. A Form 25-NSE will be filed with the SEC to officially remove the shares from listing.

Winding Up and Liquidation

Simultaneously, shareholders should note that Iterum Therapeutics is in the process of winding up—an effective dissolution and liquidation of the Company. This process is being managed by joint provisional liquidators, Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited. The Company has stated its limited cash resources and the ongoing winding up as reasons for not filing its 2025 annual report or any further SEC filings.

Shareholders are cautioned that the outcome of the winding up process remains highly uncertain. Critical factors include:

• The approval by the Irish High Court of the winding up petition;
• The possibility of an orderly winding up of the business;
• The timing and process of delisting from Nasdaq;
• Potential proceedings by third parties regarding the winding up or asset sales;
• Uncertainties about the ability of shareholders or other stakeholders to realize any value or recovery as part of the winding up process;
• The Company’s expectation that it will no longer file reports with the SEC.

Forward-Looking Statements and Risks

The Company has issued a cautionary note regarding forward-looking statements. These statements are subject to known and unknown risks, uncertainties, and additional factors, including but not limited to those described in the Company’s previous SEC filings under “Risk Factors.” Actual future results may differ materially from what is currently anticipated, and there is no assurance that shareholders will receive any value from the winding up process.

Authority and Capacity of Signatories

The 8-K filing clarifies that the joint provisional liquidators are signing solely in their capacity as provisional liquidators and accept no personal liability related to the winding up of Iterum Therapeutics plc.

What Shareholders Must Know

• Delisting and Trading Halt: Shareholders will no longer be able to trade Iterum Therapeutics shares on Nasdaq after March 31, 2026.
• Uncertainty of Value and Recovery: There is a significant risk that shareholders may not realize any value from their holdings as the Company is winding up and does not plan further SEC disclosures.
• Legal and Procedural Risks: The Irish High Court must approve the winding up petition, and there may be additional legal or creditor actions impacting the process.
• No Further Financial Reporting: The Company will not issue future financial statements or updates to the SEC, limiting transparency for investors.

This news is highly price sensitive and likely to have a significant negative impact on the Company’s share value, as the delisting and winding up process signal the cessation of Iterum Therapeutics as an ongoing concern.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information provided is based on public filings and may be subject to change without notice. Investors should consult with their own advisors and consider all risks before making any investment decisions. The author and publisher accept no liability for any losses arising from reliance on the information contained herein.

View Iterum Therapeutics plc Historical chart here